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BACKGROUND
The role of supine positioning after acute stroke in improving cerebral blood flow and 
the countervailing risk of aspiration pneumonia have led to variation in head position-
ing in clinical practice. We wanted to determine whether outcomes in patients with 
acute ischemic stroke could be improved by positioning the patient to be lying flat 
(i.e., fully supine with the back horizontal and the face upwards) during treatment to 
increase cerebral perfusion.
METHODS
In a pragmatic, cluster-randomized, crossover trial conducted in nine countries, we as-
signed 11,093 patients with acute stroke (85% of the strokes were ischemic) to receive 
care in either a lying-flat position or a sitting-up position with the head elevated to at 
least 30 degrees, according to the randomization assignment of the hospital to which 
they were admitted; the designated position was initiated soon after hospital admission 
and was maintained for 24 hours. The primary outcome was degree of disability at 90 
days, as assessed with the use of the modified Rankin scale (scores range from 0 to 6, 
with higher scores indicating greater disability and a score of 6 indicating death).
RESULTS
The median interval between the onset of stroke symptoms and the initiation of the 
assigned position was 14 hours (interquartile range, 5 to 35). Patients in the lying-flat 
group were less likely than patients in the sitting-up group to maintain the position for 
24 hours (87% vs. 95%, P<0.001). In a proportional-odds model, there was no significant 
shift in the distribution of 90-day disability outcomes on the global modified Rankin 
scale between patients in the lying-flat group and patients in the sitting-up group (un-
adjusted odds ratio for a difference in the distribution of scores on the modified Rankin 
scale in the lying-flat group, 1.01; 95% confidence interval, 0.92 to 1.10; P = 0.84). Mor-
tality within 90 days was 7.3% among the patients in the lying-flat group and 7.4% 
among the patients in the sitting-up group (P = 0.83). There were no significant between-
group differences in the rates of serious adverse events, including pneumonia.
CONCLUSIONS
Disability outcomes after acute stroke did not differ significantly between patients 
assigned to a lying-flat position for 24 hours and patients assigned to a sitting-up 
position with the head elevated to at least 30 degrees for 24 hours. (Funded by the 
National Health and Medical Research Council of Australia; HeadPoST ClinicalTrials 
.gov number, NCT02162017.)
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The prognosis in patients with acute ischemic stroke is determined according to the location and size of the occluded 
cerebral vessel,1 the extent of collateral blood 
flow,1-3 and the time to reperfusion therapy.4 
Small, nonrandomized studies have indicated 
that the lying-flat position (i.e., fully supine with 
the back horizontal and the face upwards) in-
creases blood flow in major arteries5,6 and im-
proves oxygenation of the brain,7,8 whereas a 
sitting-up body position with the head elevated 
(hereafter referred to as the “sitting-up position”) 
may reduce intracranial pressure in patients with 
large hemispheric ischemic stroke.9 Uncertainty 
over the role of head positioning after acute 
stroke and the potential risks of cardiopulmo-
nary dysfunction and aspiration pneumonia10 
have led to ambiguous guidelines11 and variation 
in clinical practice.12 The Head Positioning in 
Acute Stroke Trial (HeadPoST) compared the ef-
fects of the lying-flat position with those of the 
sitting-up position, initiated soon after a stroke 
and maintained for 24 hours, in a range of 
health care settings and in patients with various 
types of acute stroke.
Me thods
Trial Design and Oversight
HeadPoST was an international, multicenter, 
cluster-randomized, crossover, open-label trial 
with blinded outcome evaluation; the trial was 
conducted at 114 hospitals (centers) in nine 
countries (Table S1 in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org). Details of the design and statisti-
cal analysis plan of the trial have been published 
previously,13,14 and the trial protocol is available 
at NEJM.org. The trial was funded by the Na-
tional Health and Medical Research Council of 
Australia. Members of an international steering 
committee designed the trial and were respon-
sible for the conduct of the trial and the report-
ing of the results. Staff at the George Institute 
for Global Health coordinated the trial, managed 
the database, and performed the analyses. The 
first author wrote the initial and subsequent 
drafts of the manuscript. All the authors par-
ticipated in drafting the manuscript, vouch for 
the accuracy and completeness of the data and 
for the fidelity of this report to the trial proto-
col, and approved the decision to submit the 
manuscript for publication.
The protocol was approved by all regulatory 
authorities and ethics committees at the partici-
pating centers. A senior executive officer at each 
hospital acted as a “guardian” (as part of the 
cluster-randomized trial design) and provided 
consent at an institutional level for head posi-
tioning to be implemented as a low-risk inter-
vention to clusters of patients as part of routine 
care; written informed consent was subsequent-
ly obtained from the patients or their approved 
surrogates for the collection of medical data and 
participation in the follow-up assessments.
A statistician who was not otherwise involved 
in the trial generated the randomized assignment 
sequence for the hospitals, stratified according 
to country. In accordance with the protocol, the 
participating centers implemented the first as-
signed intervention until a target number of 
consecutive patients was reached; then, in the 
crossover phase, the centers implemented the 
second intervention in a similar number of con-
secutive patients.
Patients
Patients were eligible for inclusion in the trial if 
they were 18 years of age or older, presented to 
the emergency department or an inpatient ser-
vice at a participating center, and received a 
clinical diagnosis of acute stroke. Patients with 
acute intracerebral hemorrhage (but not sub-
arachnoid hemorrhage) were purposefully in-
cluded in the trial to facilitate implementation of 
the intervention in consecutive patients and to 
explore the effects of head positioning on the 
risk of cerebral edema and pneumonia. Patients 
were excluded if the local clinician-investigator 
considered that the assigned head position could 
not be maintained consistently, if the confirmed 
diagnosis was a transient ischemic attack, or if 
the patient declined to participate in the trial. 
Patients were also excluded if there was a clear 
indication for, or contraindication to, either of 
the head positions.15
Interventions
The assigned head position was initiated in pa-
tients as soon as possible in the emergency de-
partment or other assessment area and was 
maintained during transfer to an inpatient unit. 
A Quick Take 
is available at 
NEJM.org
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Patients were asked to strictly maintain the as-
signed position for the next 24 hours, including 
when eating, drinking, and toileting unless they 
found it too uncomfortable to maintain or un-
less it was considered by the investigator, pa-
tient, or caregiver to be harmful, in which case 
the position could be interrupted for up to three 
nonconsecutive periods of under 30 minutes. 
Patients who were assessed as having dysphagia 
were given no food or drink or received nasogas-
tric tube feeding or a modified diet while remain-
ing in the assigned body position. For the pa-
tients in the lying-flat group, bolus rather than 
continuous feeding was recommended in those 
with a nasogastric tube, and graded elevation of 
the head and mobilization with toilet privileges 
commenced after 24 hours. For the sitting-up 
position, the head of the patient was elevated to 
at least 30 degrees by having the head of the bed 
raised mechanically or by the use of pillows if 
the bed was nonmechanical; the angle was con-
firmed with a protractor. Patients in this group 
were allowed toilet privileges outside the bed 
according to their level of mobility. All other 
management was left to the discretion of the 
investigators in relation to standards of care 
recommended in their own national guidelines.
Data Collection
Demographic and clinical data were collected at 
the time of presentation and included scores on 
the National Institutes of Health Stroke Scale 
(NIHSS; scores range from 0 to 42, with higher 
scores indicating greater severity of stroke).16 A 
24-hour bedside diary was maintained to record 
vital signs, lowest oxygen saturation, and inter-
ruption (with time and reason) of the assigned 
head position. Follow-up data were collected at 
7 days (or at hospital discharge, if it occurred 
before 7 days), unless death occurred earlier; 
data included final diagnosis, repeat NIHSS 
scores, and assessment of disability on the 
modified Rankin scale (a measure of disability 
in which scores range from 0 to 6, with 0 indi-
cating no symptoms at all; 1, no clinically sig-
nificant disability despite symptoms; 2, slight 
disability; 3, moderate disability requiring some 
help; 4, moderately severe disability requiring 
assistance with daily living; 5, severe disability, 
bed-bound, and incontinent; and 6, death).17,18 
Trained staff, who were unaware of the random-
ized intervention, contacted patients by telephone 
for the 90-day assessment using the simplified 
version of the modified Rankin scale,19,20 which 
requires only “yes” or “no” answers to structured 
questions. The European Quality of Life Group 
5-Dimension Self-Report Questionnaire (EQ-5D)21 
was also used to assess quality of life with re-
spect to mobility, self-care, usual activities, pain 
or discomfort, and anxiety or depression (scores 
range from 1 to 3, with 1 indicating no problems, 
2 some or moderate problems, and 3 severe 
problems). The EQ-5D includes a visual-analogue 
scale as a single index of self-rated health status 
(with the scale ranging from 0 [worst imagin-
able health state] to 100 [best imaginable health 
state]).
Outcomes
The primary outcome was the degree of disabil-
ity at 90 days, which was analyzed as an ordinal 
outcome across levels of disability on the modi-
fied Rankin scale.22 Secondary outcomes included 
death or major disability (modified Rankin scale 
scores of 3 to 6) at 90 days, death within 90 days 
after stroke, duration of hospital stay, the indi-
vidual components of the EQ-5D at 90 days, the 
distribution of levels across the modified Rankin 
scale at 7 days, and the distribution of seven 
levels of increasing neurologic impairment ac-
cording to categorical scores on the NIHSS or 
death at 7 days. Serious adverse events, including 
pneumonia (for which additional clinical infor-
mation was obtained) were recorded through 
trial completion. (Additional details on out-
comes and serious adverse events are provided in 
the Supplementary Appendix.)
Statistical Analysis
We estimated that at least 100 patients with 
acute ischemic stroke would need to be assigned 
to a head position at each hospital (i.e., 50 pa-
tients per intervention phase [or “period”]) 
across 120 centers (a total of 12,000 patients) for 
the study to have 90% power to detect a 16% or 
greater relative shift in levels of disability out-
come between intervention groups at 90 days in 
the ordinal logistic-regression analysis, at an 
alpha level of 0.05.3 This calculation was based 
on conservative estimates of a 10% dropout rate 
of participating centers and a crossover rate of 
5% and loss-to-follow-up rate of 10% among 
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patients at each center, together with an intra-
cluster correlation of 0.03 and no interperiod 
correlation. This sample size was also estimated 
to provide 90% power to detect a 16% or greater 
relative shift in levels of neurologic function on 
the basis of categorical NIHSS scores or death at 
7 days, at least a 30% lower relative rate of death 
by 90 days, and a 2-day shorter length of hospital 
stay in the lying-flat group than in the sitting-up 
group. However, the target number of patients 
for recruitment at each center was increased to 
140 (i.e., 70 patients per intervention group) to 
account for the potential of poor implementa-
tion of head positioning among patients during 
the initial and crossover phases and to account 
for the inclusion of patients with acute intrace-
rebral hemorrhage; a sample of 2800 patients 
with acute intracerebral hemorrhage was esti-
mated to provide 90% power to detect a 25% or 
greater improvement (shift) in the 90-day dis-
ability outcome associated with the sitting-up 
position, a 25% or greater improvement in odds 
(shift) of survival and categorical NIHSS score at 
7 days, at least a 33% lower rate of death by 90 
days, and a 2-day shorter length of hospital stay, 
at an alpha level of 0.05 (see the Supplementary 
Appendix).
Using an intention-to-treat approach, we per-
formed the primary analysis of the intervention 
effect, as assessed by means of the modified 
Rankin scale, with an ordinal, logistic-regression, 
hierarchical, mixed model with four adjustment 
variables (fixed intervention effect [lying flat vs. 
sitting up], fixed period effect, random cluster 
effect, and effect of the interaction between ran-
dom cluster and period).23,24 These primary pre-
specified analyses were given the term “unad-
justed.” Consistency of intervention effect across 
seven prespecified subgroups (defined according 
to age, sex, major country and region groupings, 
baseline NIHSS score, time from stroke onset to 
commencement of intervention, major pathologic 
subtype, and sequence of head positioning at the 
hospital) was assessed by means of tests for inter-
action. Prespecified sensitivity analyses included 
two adjusted models. The first model adjusted 
for country (grouped as United Kingdom and 
Australia; China and Taiwan; India and Sri 
Lanka; and Chile, Brazil, and Colombia), modi-
fied Rankin scale score before stroke as a cate-
gorical variable, age as a continuous variable, 
and sex, and the second model adjusted for the 
covariates in the first model, with additional co-
variates of baseline NIHSS score and history of 
stroke, heart disease, or diabetes mellitus; multi-
ple imputation was used if more than 10% of 
observations on the modified Rankin scale were 
missing.25 Similar unadjusted and adjusted analy-
ses were applied to the NIHSS score or death at 
7 days after stroke. Other efficacy analyses in-
cluded an unadjusted analysis of the distribution 
of the modified Rankin scale scores at 7 days 
and binary analyses of death and of death or 
disability (modified Rankin scale of 3 to 6) at 90 
days; these binary analyses were performed with 
the use of hierarchical logistic-regression models. 
An independent data and safety monitoring board 
monitored the trial progress and safety; no for-
mal interim analysis was performed. All reported 
P values are two-sided, and no adjustment was 
made for multiple comparisons. All analyses 
were performed with SAS software, version 9.3 
(SAS Institute).
R esult s
Patients
From March 2, 2015, to November 29, 2016, a 
total of 11,093 of the 22,632 screened patients 
across 114 hospitals were assigned to a random-
ized head position (Fig. 1); 5295 patients were 
assigned to the lying-flat position and 5798 to 
the sitting-up position. Baseline characteristics 
of the patients are summarized in Table 1 (fur-
ther details are provided in Tables S2 through S4 
in the Supplementary Appendix). The mean age 
was 68 years (23% were ≥80 years of age), 40% 
were female, and 85% had acute ischemic stroke. 
The median pretreatment NIHSS score was 4 (in-
terquartile range, 2 to 8). The time from the 
onset of stroke to commencement of the head 
position was 14.0 hours (interquartile range, 5.0 
to 35.0), and the median time from presentation 
at the hospital to commencement of the head 
position was 7.0 hours (interquartile range, 2.0 to 
26.0) in the lying-flat group and 7.0 hours (inter-
quartile range, 2.0 to 27.0) in the sitting-up group.
Intervention and Reestimation of Sample Size
The median time in the assigned head position was 
significantly less among the patients in the lying-
flat group than among the patients in the sitting-
up group (23.3 hours [interquartile range, 20.0 
to 24.0] vs. 24.0 hours [interquartile range, 23.0 
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Figure 1. Randomization, Enrollment, and Follow-up.
In the lying‑flat group, patients were positioned to lie fully supine with the back horizontal and the face upwards. In the sitting‑up group, 
patients were positioned to sit up with the head elevated to at least 30 degrees. TIA denotes transient ischemic attack.
116 Underwent randomization
182 Hospitals were invited to participate
57 Were assigned to implement the lying-flat
position (initial phase) and then the
sitting-up position (crossover phase)
59 Were assigned to implement the sitting-up
position (initial phase) and then the
lying-flat position (crossover phase)
6407 Patients were
screened
5371 Patients were
screened
1 Was not activated
to commence
recruitment
1 Was not activated
to commence
recruitment
3562 Were excluded
930 Had other
condition
567 Had long delay
528 Did not have
stroke
444 Had TIA
433 Declined to
participate
323 Had rapid
transfer
51 Were a part of
other research
40 Died
13 Were prior
participants
1 Was <18 yr
of age
232 Had other
reasons
2604 Were excluded
430 Had other
condition
452 Had long delay
492 Did not have
stroke
323 Had TIA
240 Declined to
participate
469 Had rapid
transfer
15 Were a part of
other research
37 Died
26 Were prior
participants
120 Had other
reasons
2514 Were excluded
349 Had other 
condition
398 Had long delay
442 Did not have
stroke
355 Had TIA
294 Declined to
participate
332 Had rapid
transfer
32 Were a part of
other research
40 Died
18 Were prior
participants
1 Was <18 yr
of age
253 Had other
reasons
2859 Were excluded
570 Had other
condition
374 Had long delay
474 Did not have
stroke
399 Had TIA
338 Declined to
participate
437 Had rapid
transfer
12 Were a part of
other research
21 Died
17 Were prior
participants
217 Had other
reasons
343 Declined to
 participate or were
lost to follow-up
359 Declined to
 participate or were
lost to follow-up
367 Declined to
 participate or were
lost to follow-up
276 Declined to
 participate or were
lost to follow-up
5545 Patients were
screened
5309 Patients were
screened
2502 (88%) Were included
in analysis
2408 (87%) Were included
in analysis
2664 (88%) Were included
in analysis
2174 (89%) Were included
in analysis
2845 Were assigned
to the lying-flat group
2767 Were assigned 
to the sitting-up group
3031 Were assigned
to the sitting-up group
2450 Were assigned
to the lying-flat group
56 Implemented the positions 58 Implemented the positions
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Characteristic
Lying Flat 
(N = 5295)
Sitting Up 
(N = 5799)
Age — yr 67.8±13.9 68.1±13.7
Female sex — no. (%)† 2140 (40.4) 2289 (39.5)
Region of recruitment — no. (%)
Australia and United Kingdom 2214 (41.8) 2547 (43.9)
China and Taiwan 2211 (41.8) 2441 (42.1)
South America, India, and Sri Lanka 870 (16.4) 810 (14.0)
Medical history — no. (%)
Hypertension 2711 (51.2) 2906 (50.1)
Any stroke 1238 (23.4) 1393 (24.0)
Coronary artery disease 690 (13.0) 849 (14.6)
Atrial fibrillation 555 (10.5) 621 (10.7)
Heart failure 166 (3.1) 246 (4.2)
Diabetes mellitus 1065 (20.1) 1156 (19.9)
Tobacco use 987 (18.6) 1137 (19.6)
A score of 0 (no symptoms) on the modified Rankin scale before 
stroke†
3218 (60.8) 3526 (60.8)
Aspirin or other antiplatelet agent use 3353 (63.3) 3656 (63.0)
Anticoagulant use 428 (8.1) 522 (9.0)
Median NIHSS score (IQR)‡ 4.0 (2.0–9.0) 4.0 (2.0–8.0)
Median time from stroke onset to intervention (IQR) — hr 14.0 (5.0–35.0) 14.0 (5.0–35.0)
Median time from hospital admission to intervention (IQR) — hr 7.0 (2.0–26.0) 7.0 (2.0–27.0)
Final diagnosis at time of hospital discharge — no. (%)§
Condition mimicking stroke 232 (4.4) 319 (5.5)
Transient ischemic attack 106 (2.0) 106 (1.8)
Acute ischemic stroke 4532 (85.6) 4953 (85.4)
Large‑artery occlusion due to substantial atheroma 1390 (30.7) 1558 (31.5)
Small‑vessel or perforating arteriole lacunar disease 1352 (29.8) 1511 (30.6)
Cardioembolism 592 (13.1) 643 (13.0)
Other or uncertain cause 1195 (26.4) 1235 (25.3)
Primary intracerebral hemorrhage 420 (7.9) 511 (8.8)
*  Plus–minus values are means ±SD. There were no significant differences in baseline characteristics between the groups 
with the exception of region of recruitment (P = 0.002), history of coronary artery disease (P = 0.02), and history of heart 
failure (P = 0.002). In the lying‑flat group, patients were positioned to lie fully supine with the back horizontal and the 
face upwards. In the sitting‑up group, patients were positioned to sit up with the head elevated to at least 30 degrees. 
IQR denotes interquartile range, and NIHSS National Institutes of Health Stroke Scale.
†  Scores on the modified Rankin scale range from 0 to 6, with higher scores indicating more severe disability and a score 
of 6 indicating death.
‡  Scores on the NIHSS range from 0 to 42, with higher scores indicating more severe neurologic deficits.
§  Final diagnosis at time of hospital discharge was reported by the clinician‑investigator on the basis of brain imaging 
and other investigations.
Table 1. Characteristics of the 11,093 Patients with Acute Stroke at Baseline.*
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to 24.0], P<0.001), and the patients in the lying-
flat group were more likely than the patients in 
the sitting-up group to prematurely cease the 
position within 24 hours after initiation (13.0% 
vs. 4.2%, P<0.001). However, there were no sig-
nificant between-group differences with respect 
to blood oxygen saturation, blood pressure 
levels, or other aspects of management. Out-
come assessments of scores on the modified 
Rankin scale could not be performed in 619 
patients (11.7%) in the lying-flat group and in 
726 patients (12.5%) in the sitting-up group be-
cause the patients declined to participate or were 
lost to follow-up (Fig. 1). The modes of assess-
ment of modified Rankin scale scores (i.e., face-
to-face assessment or assessment by telephone 
call to caregiver, telephone call to patient, tele-
phone call to patient’s physician, or other or un-
coded) were balanced between groups. (Addi-
tional details on the interventions are provided 
in Tables S5 through S7 and Figs. S1 through 
S3 in the Supplementary Appendix.)
Because the final number of centers that re-
cruited patients was lower than anticipated and 
because the mean number of patients with acute 
ischemic stroke was 13 fewer than estimated per 
cluster per period, the study power was reesti-
mated with the observed degree of correlation in 
patient characteristics between clusters and dif-
ferent periods. On the basis of the mean dura-
tion in the assigned head position, we estimated 
that 13% of the patients with acute ischemic 
stroke crossed over from the lying-flat to the 
sitting-up position and 6% crossed over from the 
sitting-up to the lying flat position. Although 
the intracluster correlation was higher than ex-
pected (0.083), this was compensated by a high 
correlation of patients from different periods in 
the same cluster (i.e., interperiod correlation of 
0.076). In accordance with these calculated in-
tercluster and interperiod correlation values and 
assumptions of adherence to the randomized 
positions, the trial was estimated to have retained 
90% power to detect a common odds ratio of 
0.84 (additional details are provided in the Sup-
plementary Appendix).
Primary and Secondary Outcomes
There was no significant between-group differ-
ence in the primary outcome of the degree of 
disability at 90 days, as assessed by scores on 
the modified Rankin scale (unadjusted odds ratio 
for a difference in the distribution of scores on 
the modified Rankin scale in the lying-flat group, 
1.01; 95% confidence interval [CI], 0.92 to 1.10; 
P = 0.84) (Fig. 2). Sensitivity analyses with adjust-
ment and with the use of multiple imputation for 
missing modified Rankin scale scores showed 
results similar to those of the primary analysis 
(Table 2); in addition, when the outcomes of 
patients with ischemic stroke and intracerebral 
hemorrhage were analyzed separately, the results 
were similar to the findings from the primary 
analysis (Tables S8 and S9 in the Supplementary 
Appendix).
Death or major disability (modified Rankin 
scale score of 3 to 6) at 90 days occurred in 
38.9% of the patients in the lying-flat group and 
in 39.7% of the patients in the sitting-up group 
(odds ratio in the lying-flat group, 0.94; 95% CI, 
0.85 to 1.05; P = 0.25), and death within 90 days 
after stroke occurred in 7.3% in the lying-flat 
group and in 7.4% in the sitting-up group (odds 
Figure 2. Intervention Effects in the Lying-Flat Group and the Sitting-Up 
Group at 90 Days, According to Modified Rankin Scale Score.
There was no significant shift in the distribution of 90‑day disability out‑
comes on the global modified Rankin scale between patients in the lying‑
flat group and patients in the sitting‑up group (odds ratio for a difference 
in the distribution of scores on the modified Rankin scale in the lying‑flat 
group, 1.01; 95% confidence interval, 0.92 to 1.10; P = 0.84 by a hierarchi‑
cal linear mixed model with adjustment for the design by including a fixed 
group effect, a fixed period effect, a random cluster effect, and an effect  
of the interaction between random cluster and period). Scores on the modi‑
fied Rankin scale range from 0 to 6, with 0 indicating no symptoms, 1 no 
clinically significant disability despite symptoms, 2 slight disability, 3 moder‑
ate disability, 4 moderately severe disability, 5 severe disability, and 6 death. 
The odds ratios and 95% confidence intervals were adjusted for the cluster‑
randomized, crossover design effect.
0 10 20 30 40 50 60 70 80 90 100
Patients (%)
Modified Rankin Scale Score
Sitting Up
Lying Flat
0 1 2 3 4 5 6
18.2 16.2 6.433.6 8.6 8.28.8
36.415.9 15.28.8 6.19.5 8.1
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ratio in the lying-flat group, 0.98; 95% CI, 0.85 to 
1.14; P = 0.83) (Table 2). No significant between-
group differences were evident for other out-
comes, except for scores on the visual-analogue 
scale of the EQ-5D, which favored the lying-flat 
group (P = 0.009). (See also Figs. S4 and S5 and 
Tables S10 and S11 in the Supplementary Ap-
pendix.)
In prespecified subgroup analyses, there was 
no significant heterogeneity in the intervention 
effect with respect to the primary outcome or 
the secondary outcomes of categorical scores on 
the NIHSS or death or scores on the modified 
Rankin scale at 7 days. Post hoc analysis indi-
cated no heterogeneity in the intervention effect 
according to quintiles of baseline NIHSS scores 
Outcome
Lying Flat 
(N = 4676)
Sitting Up 
(N = 5072)
Odds Ratio 
with Sitting Up  
as Reference 
(95% CI) P Value
no./total no. (%)
Primary outcome
Levels of disability on the modified Rankin scale at 90 days* 1.01 (0.92–1.10)† 0.84
0 — No symptoms at all 745/4676 (15.9) 922/5072 (18.2)
1 — No clinically significant disability despite symptoms 1704/4676 (36.4) 1703/5072 (33.6)
2 — Slight disability 410/4676 (8.8) 438/5072 (8.6)
3 — Moderate disability requiring some help 711/4676 (15.2) 820/5072 (16.2)
4 — Moderately severe disability requiring assistance with 
daily living
444/4676 (9.5) 446/5072 (8.8)
5 — Severe disability, bed‑bound, and incontinent 283/4676 (6.1) 326/5072 (6.4)
6 — Death 379/4676 (8.1) 417/5072 (8.2)
Secondary outcomes
Death or disability according to modified Rankin scale scores  
of 3 to 6 at 90 days
1817/4676 (38.9) 2009/5062 (39.7) 0.94 (0.85–1.05)‡ 0.25
Death within 90 days after stroke 379/5185 (7.3) 417/5669 (7.4) 0.98 (0.85–1.14)‡ 0.83
Levels of disability on the modified Rankin scale at 7 days* 1.02 (0.93–1.12)§ 0.67
0 — No symptoms at all 835/5240 (15.9) 915/5732 (16.0)
1 — No significant disability despite symptoms 1384/5240 (26.4) 1614/5732 (28.2)
2 — Slight disability 1009/5240 (19.3) 1102/5732 (19.2)
3 — Moderate disability requiring some help 707/5240 (13.5) 731/5732 (12.8)
4 — Moderately severe disability requiring assistance  
with daily living
771/5240 (14.7) 798/5732 (13.9)
5 — Severe disability, bed‑bound, and incontinent 459/5240 (8.8) 496/5732 (8.7)
6 — Death 75/5240 (1.4) 76/5727 (1.3)
Categorical scores on the NIHSS or death at 7 days* 0.98 (0.90–1.08)¶ 0.71
1 — Scores 0–4 3483/5108 (68.2) 3851/5608 (68.7)
2 — Scores 5–9 817/5108 (16.0) 884/5608 (15.8)
3 — Scores 10–14 410/5108 (8.0) 433/5608 (7.7)
4 — Scores 15–19 174/5108 (3.4) 208/5608 (3.7)
5 — Scores 20–24 103/5108 (2.0) 94/5608 (1.7)
6 — Scores ≥25 46/5108 (0.9) 62/5608 (1.1)
7 — Death 75/5108 (1.5) 76/5608 (1.4)
Table 2. Trial Outcomes and Safety.
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or time from the onset of stroke symptoms to 
commencement of the intervention. (See also 
Figs. S6 through S10 in the Supplementary Ap-
pendix.)
Adverse Effects
No significant difference in the rate of serious 
adverse events was observed between the lying-
flat group and the sitting-up group (14.3% and 
13.5%, respectively; P = 0.51) (Table 2). In par-
ticular, no significant between-group difference 
was observed in the rate of pneumonia. (See also 
Tables S12 and S13 in the Supplementary Ap-
pendix.)
Discussion
In this cluster-randomized trial involving patients 
with acute stroke in a range of health care set-
tings, we found no significant difference between 
the implementation — at a median of 14 hours 
after the onset of stroke — of the lying-flat head 
position and the sitting-up position with respect 
to the primary outcome of level of disability at 
90 days. There were also no significant differ-
ences in mortality or in the rates of serious ad-
verse events, including pneumonia.
Our decision to undertake a pragmatic cluster 
clinical trial was based on the need to avoid con-
tamination between individual patients (i.e., an 
assigned intervention spilling over into the other 
group that was assigned to another intervention, 
thereby diluting the difference between the two 
randomized groups that are meant to be defined 
by each specific intervention)26; the crossover 
component facilitated the recruitment of the 
sample size necessary to assess small differences 
in clinical outcomes between interventions. The 
potentially confounding effect of management 
strategies for acute stroke appears to be low, and 
Outcome
Lying Flat 
(N = 4676)
Sitting Up 
(N = 5072)
Odds Ratio 
with Sitting Up  
as Reference 
(95% CI) P Value
no./total no. (%)
Safety
Patients with any serious adverse event 756/5295 (14.3) 784/5798 (13.5) 1.05 (0.91–1.20)‡ 0.51
Patients with pneumonia 164/5295 (3.1) 198/5798 (3.4) 0.86 (0.68–1.08)‡ 0.19
*  The common odds was estimated in an ordinal logistic‑regression model and indicates the increase in odds of moving from a lower level of 
disability or stroke severity to a higher one in the lying‑flat group relative to the sitting‑up group. An odds ratio of higher than 1 favors the 
sitting‑up position.
†  The odds ratio (with 95% confidence interval) and the corresponding P value for a difference in the distribution of scores on the modified 
Rankin scale at 90 days were obtained with the use of a hierarchical linear mixed model with adjustment for the design, including a fixed 
group effect, a fixed period effect, a random cluster effect, and an effect of the interaction between random cluster and period; this was the 
primary analysis and was given the term “unadjusted.” Three adjusted analysis were performed: the first included covariates of country, 
modified Rankin scale score before stroke, age, and sex (odds ratio, 1.05; 95% CI, 0.96 to 1.15; P = 0.30); the second included the covariates 
in the first adjusted analysis plus additional covariates of baseline NIHSS score and history of heart disease, stroke, or diabetes mellitus 
(odds ratio, 1.03; 95% CI, 0.94 to 1.13; P = 0.55); and the third included the covariates in the second adjusted analysis as well as multiple 
imputation because more than 10% of scores on the modified Rankin scale were missing (odds ratio, 1.03; 95% CI, 0.94 to 1.13; P = 0.50).
‡  The odds ratio (with 95% confidence interval) and the corresponding P value were obtained with the use of a hierarchical mixed logistic‑ 
regression model. This analysis was given the term “unadjusted.”
§  The odds ratio (with 95% confidence interval) and the corresponding P value for a difference in the distribution of scores on the modified 
Rankin scale at 7 days were obtained with the use of a hierarchical linear mixed model with adjustment for the design, including a fixed 
group effect, a fixed period effect, a random cluster effect, and an effect of the interaction between random cluster and period. This analysis 
was given the term “unadjusted.”
¶  The odds ratio (with 95% confidence interval) and the corresponding P value for a difference in the distribution of scores on the NIHSS or 
survival at 7 days were obtained with the use of a hierarchical linear mixed model with adjustment for the design, including a fixed group effect, 
a fixed period effect, a random cluster effect, and an effect of the interaction between random cluster and period. This analysis was given 
the term “unadjusted.” Three adjusted analysis were performed: the first included covariates of country, modified Rankin scale score before 
stroke, age, and sex (odds ratio, 1.01; 95% CI, 0.92 to 1.10; P = 0.91); the second included the covariates in the first adjusted analysis plus 
additional covariates of baseline NIHSS score and history of heart disease, stroke, or diabetes mellitus (odds ratio, 0.97; 95% CI, 0.88 to 
1.07; P = 0.52); and the third included the covariates in the second adjusted analysis as well as multiple imputation because more than 10% 
of scores on the modified Rankin scale were missing (odds ratio, 0.97; 95% CI, 0.88 to 1.07; P = 0.51).
Table 2. (Continued.)
n engl j med 376;25 nejm.org June 22, 20172446
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
completion of the statistical analysis plan before 
patient follow-up was concluded eliminated the 
potential for analytic bias. Although clinicians 
could not be unaware of the assigned head posi-
tions because of the practical requirements of a 
nursing care intervention, any selection bias in-
troduced by differential recruitment to clusters 
appears to be low. The risk of bias in interven-
tion assignment was minimized by the use of 
central randomization, and central blinded assess-
ment of the primary outcome limited observer 
bias. The results are generalizable, because 
participating centers included patients with a 
variety of types of stroke and represented various 
types of clinical services,27,28 including metro-
politan and rural hospitals and various resource 
settings.
The negative results of this trial suggest that 
any modification of cerebral blood flow that 
may have occurred as a result of head position-
ing initiated within 24 hours was insufficient to 
reduce the neurologic deficit associated with 
acute stroke. Although we did not reach the 
planned sample size, an analysis of the degree 
to which clusters were related to each other in-
dicated that the trial retained power to assess 
the prespecified intervention effect. Because the 
primary analysis provided an odds ratio for the 
intervention effect that was close to 1.0 and had 
a narrow confidence interval, it is unlikely that a 
true difference in the disability outcome was 
missed. Although there was no heterogeneity of 
the intervention effect with respect to the primary 
outcome in prespecified subgroups, these analy-
ses had low statistical power. Most of the pa-
tients in our trial had the assigned head position 
implemented after the time window for reperfu-
sion with thrombolytic or endovascular treatment 
had passed, and the patients had mostly mild 
neurologic deficits from a range of causes of 
stroke. It is possible that earlier initiation of 
head position after the onset of symptoms when 
the ischemic penumbra is potentially modifiable 
may have produced different results.
The rate of pneumonia was lower in our trial 
than in some other series29 but was similar to 
the rates in stroke registries27 and in a retrospec-
tive study of lying-flat positioning in patients with 
acute ischemic stroke.30 The low rates in this 
trial might relate to careful assessment and care 
of patients, including the use of dysphagia screen-
ing protocols and feeding regimens, as well as 
the exclusion of high-risk patients such as those 
who underwent intubation.
In conclusion, the lying-flat head position, as 
compared to the sitting-up position, initiated 
early after presentation and maintained for 24 
hours, did not alter disability outcomes in pa-
tients with acute stroke.
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